|
Ozone Exposure and Dose Delivered to Human Lungs Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Ozone Exposure and Dose Delivered to Human Lungs conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Ozone Exposure and Dose Delivered to Human Lungs Clinical research trials and Ozone Exposure and Dose Delivered to Human Lungs health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Ozone Exposure and Dose Delivered to Human Lungs. Ozone Exposure and Dose Delivered to Human Lungs Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Ozone Exposure and Dose Delivered to Human Lungs clinical trial. Human subjects often get the best healthcare possible for their Ozone Exposure and Dose Delivered to Human Lungs condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "O" Clinical Trials Conditions > Ozone Exposure and Dose Delivered to Human Lungs  Ozone Exposure and Dose Delivered to Human Lungs
Ozone Exposure and Dose Delivered to Human Lungs
For Condition: Lung Disease
Status: Recruiting
Sponsor(s): National Institute of Environmental Health Sciences (NIEHS) ,
Synopsis: Ozone is an air pollutant formed in at ground level by the chemical reaction between oxygen and automobile emissions in the presence of sunlight. The objective of this research is to determine how lung size, chemical composition, and normal functioning of the respiratory system affect the amount of inhaled ozone that reaches internal sites of tissue irritation and damage. To infer the distribution of inhaled ozone within the respiratory system, measurements of ozone concentration and air flow are made just outside the nose and mouth of healthy subjects who breathe laboratory-generated, ozonated air for about one hour. Biochemical composition of respiratory mucus is then inferred from nasal washings made with salt water. The amount of ozone that a subject retains in one of these experiments is less than the daily exposure in a large city such as New York or Los Angeles.
Details: Ozone is a ground-level air pollutant generated primarily by the photochemical reaction of automobile emissions. The primary objective of this research is to determine the mechanism by which anatomical, physiological, and biochemical factors influence the longitudinal distribution of respiratory ozone dose that is delivered to respiratory tissue during a particular exposure condition. The specific aims are: 1)test the hypothesis that an increase in respiratory flow increases the sensitivity of ozone dose to antioxidant levels in the epithelial lining fluid. Ozone absorption will be measured in the nose of healthy nonsmokers at different nasal flows while antioxidant levels are measured in nasal liquid; 2)test the hypothesis that the continuous inhalation of ozone and copollutant gases affects antioxidant levels in the epithelial lining fluid, thereby modulating the ozone dose. Ozone absorption and antioxidant levels in nasal lavage will be intermittently measured in the nose of healthy nonsmokers while these subjects are continuously exposed to clean air, ozone, nitrogen dioxide or sulfur dioxide during quiet nasal breathing for two hours;3)test the hypothesis that antioxidant concentrations in epithelial lining fluid are directly related to plasma concentrations so that ozone absorption are modulated by the appropriate pharmacological or dietary interventions. The longitudinal distribution of ozone absorption will be measured throughout the conducting airways of healthy nonsmokers during quiet nasal breathing. Measurements will be repeated at baseline conditions, after using probenecid to pharmacologically reduce systemic urate, and after vitamin C supplementation to increase systemic abscorbate; 4)quantify the reaction kinetics between ozone and antioxidants in epithelial lining fluid. Samples of nasal liquid will be reacted with a controlled flow of ozone in a miniature bioreactor to determine the reaction rate constant and reaction order of ozone consumption; and 5)further develop a single-path diffusion model. Respiratory absorption as well as in vitro reaction kinetics data will be used to validate a mathematical ozone dosimetry model that can predict the longitudinal distribution of ozone dose to airway tissue.
Eligibility:
Study Type: Observational, Natural History, Cross-Sectional, Convenience Sample, Prospective Study
Minimum Age/Maximum Age: 18 Years/30 Years
Genders: Both
Protocol Entry Criteria: A subject will be enrolled in the study only if he or she: has not smoked within the past 3 years; and does not have hay fever, asthma, allergic rhinitis, nasal breathing disorders or anatomical abnormalities, chronic respiratory disease, or any other chronic diseases. Women will not be included in the study if they are pregnant. Subjects who regularly take mediation will be excluded from the study.
Total Enrollment: 50
Location and Contact Information:
Overall Study Official:
JamesUltman, Principal Investigator, Pennsylvania State University
General Clinical Research Center, Penn State University *Recruiting*
University Park, Pennsylvania, 16802
United States
Recruiting Lawrence Sinoway 717-531-6853
Additional Information:
Study ID Numbers: 6075-CP-001; R01-ES06075
Study Start Date: July 1998
Record last reviewed: July 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00013780
Other Lung Disease Studies:
1. Effects of Endotoxin in Normal Human Volunteers
2. Ozone Exposure and Dose Delivered to Human Lungs
3. Study of the Disease Process of Lymphangioleiomyomatosis
4. An Open-Label Study of the Safety of Interferon gamma-1b in Patients with IPF
5. Segmental Bronchoalveolar Lavage
Related Studies:
Other Lung Disease Clinical Trials
Other Pennsylvania Clinical Trials
Other University Park Clinical Trials
Ozone Exposure and Dose Delivered to Human Lungs
|
|
|
|
|
|
|
|
